PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Effects of alendronate on osteoporosis treatment and levels of related cytokines.

Abstract Alendronate regulates the activity of osteoclasts and healing of osteoporosis. This study investigated the effect of alendronate on bone healing and changes in the levels of cytokines. Bilateral ovaries of 10 adult female rabbits were removed surgically in aseptic condition to establish the animal model of osteoporosis. Five rabbits in group A were treated with alendronate (1.15 mg·kg(-1)·week(-1)) once a week by a stomach tube, whereas the remaining 5 in group B were treated with physiological saline. The success of the animal model establishment and the efficacy of alendronate treatment were evaluated by the sports ability score and the Basso, Beattie, and Bresnahan (BBB) score; the healing degree of osteoporosis was determined by X-ray analysis and measurement of biomechanical properties; the changes in the levels of related cytokines were measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining. Treatment improved dyskinesia of the animals in group A than that in group B, with significant improvement occurring in the 4th week of treatment. The BBB score of the group A animals revealed movements similar to normal, but that of the group B animals exhibited significant motor disturbance (P < 0.01). X-ray examination showed that with time, the X-ray ratings increased. Measurement of the biomechanical properties further showed that alendronate had a positive effect on osteoporosis healing. The results of ELISA and immunohistochemistry showed that the levels of ALP, BMP-2, bFGF, and IGF-1 were upregulated in group A. In conclusion, alendronate accelerated osteoporosis healing probably via certain cytokine-related mechanism.
PMID
Related Publications

Alendronate for the treatment of osteoporosis in men.

Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.

Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.

The influence of alendronate on spine fusion in an osteoporotic animal model.

Effects of the systemic administration of alendronate on bone formation in a porous hydroxyapatite/collagen composite and resorption by osteoclasts in a bone defect model in rabbits.

Authors

Mayor MeshTerms
Keywords
Journal Title genetics and molecular research : gmr
Publication Year Start




PMID- 28362987
OWN - NLM
STAT- MEDLINE
DA  - 20170331
DCOM- 20170406
LR  - 20170406
IS  - 1676-5680 (Electronic)
IS  - 1676-5680 (Linking)
VI  - 16
IP  - 1
DP  - 2017 Mar 16
TI  - Effects of alendronate on osteoporosis treatment and levels of related cytokines.
LID - 10.4238/gmr16019485 [doi]
AB  - Alendronate regulates the activity of osteoclasts and healing of osteoporosis.
      This study investigated the effect of alendronate on bone healing and changes in 
      the levels of cytokines. Bilateral ovaries of 10 adult female rabbits were
      removed surgically in aseptic condition to establish the animal model of
      osteoporosis. Five rabbits in group A were treated with alendronate (1.15
      mg.kg-1.week-1) once a week by a stomach tube, whereas the remaining 5 in group B
      were treated with physiological saline. The success of the animal model
      establishment and the efficacy of alendronate treatment were evaluated by the
      sports ability score and the Basso, Beattie, and Bresnahan (BBB) score; the
      healing degree of osteoporosis was determined by X-ray analysis and measurement
      of biomechanical properties; the changes in the levels of related cytokines were 
      measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemical
      staining. Treatment improved dyskinesia of the animals in group A than that in
      group B, with significant improvement occurring in the 4th week of treatment. The
      BBB score of the group A animals revealed movements similar to normal, but that
      of the group B animals exhibited significant motor disturbance (P &lt; 0.01). X-ray 
      examination showed that with time, the X-ray ratings increased. Measurement of
      the biomechanical properties further showed that alendronate had a positive
      effect on osteoporosis healing. The results of ELISA and immunohistochemistry
      showed that the levels of ALP, BMP-2, bFGF, and IGF-1 were upregulated in group
      A. In conclusion, alendronate accelerated osteoporosis healing probably via
      certain cytokine-related mechanism.
FAU - Liu, C T
AU  - Liu CT
AD  - Department of Orthopedics, Medical College of Nanchang University, Nanchang,
      Jiangxi, China [email protected]
FAU - Yuan, X J
AU  - Yuan XJ
AD  - Department of Neurology, Gaoan People's Hospital, Gaoan, Jiangxi, China.
FAU - Gao, G C
AU  - Gao GC
AD  - Department of Orthopedics, The Second Affiliated Hospital of Nanchang University,
      Nanchang, Jiangxi, China.
LA  - eng
PT  - Journal Article
DEP - 20170316
PL  - Brazil
TA  - Genet Mol Res
JT  - Genetics and molecular research : GMR
JID - 101169387
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Bone Morphogenetic Protein 2)
RN  - 0 (Cytokines)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Alendronate/*administration &amp; dosage/pharmacology
MH  - Animals
MH  - Bone Density Conservation Agents/*administration &amp; dosage/pharmacology
MH  - Bone Morphogenetic Protein 2/metabolism
MH  - Cytokines/*metabolism
MH  - Disease Models, Animal
MH  - Dyskinesias/*drug therapy
MH  - Female
MH  - Fibroblast Growth Factor 2/metabolism
MH  - Humans
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Osteoporosis/*drug therapy/etiology/immunology
MH  - Ovariectomy/adverse effects
MH  - Rabbits
MH  - Treatment Outcome
MH  - Up-Regulation
EDAT- 2017/04/01 06:00
MHDA- 2017/04/07 06:00
CRDT- 2017/04/01 06:00
AID - gmr-16-01-gmr.16019485 [pii]
AID - 10.4238/gmr16019485 [doi]
PST - epublish
SO  - Genet Mol Res. 2017 Mar 16;16(1). doi: 10.4238/gmr16019485.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>